Evidence map›Paper›PMID 40034847›Full record

ArticleiScience2025

Predicting tuberculosis drug efficacy in preclinical and clinical models from

Janice J N Goh, Anu Patel, Bernard Ngara, Rob C van Wijk, Natasha Strydom, Qianwen Wang, Nhi Van, Tracy M Washington, Eric L Nuermberger, Bree B Aldridge and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Janice J N GohDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
Anu PatelDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
Bernard NgaraDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
Rob C van WijkDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
Natasha StrydomDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
Qianwen WangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
Nhi VanDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, and Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance Boston, Boston, MA, USA.
Tracy M WashingtonDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, and Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance Boston, Boston, MA, USA.
Eric L NuermbergerCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bree B AldridgeDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, and Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance Boston, Boston, MA, USA.
Christine RoubertEvotec ID (LYON) SAS, Lyon, France.
Jansy SarathyCenter for Discovery and Innovation, Hackensack Meridian School of Medicine, Hackensack Meridian Health, Nutley, NJ, USA.
Véronique DartoisCenter for Discovery and Innovation, Hackensack Meridian School of Medicine, Hackensack Meridian Health, Nutley, NJ, USA.
Rada M SavicDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.

Funding

Pharmaceutical Sciences and PharmacogenomicsT32GM142516 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Su Guo · 2022 to 2026
$2.4M
NIGMS NIH HHS T32 GM142516
6 · The paper itself

Abstract

Multiple

Indexed as

bioinformaticsbiological sciencesnatural sciencespharmacoinformaticspharmacology

Identifiers

PMID40034847
PMCPMC11875147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.